The Appetite (Eating) Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Appetite (Eating) Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Appetite (Eating) Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Appetite (Eating) Disorders and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Appetite (Eating) Disorders by 33 companies/universities/institutes. The top development phase for Appetite (Eating) Disorders is preclinical with 15 drugs in that stage. The Appetite (Eating) Disorders pipeline has 38 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Appetite (Eating) Disorders pipeline products market are: Omeros, Tryptamine Therapeutics and Orexa.
The key targets in the Appetite (Eating) Disorders pipeline products market include 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and Cannabinoid Receptor 1.
The key mechanisms of action in the Appetite (Eating) Disorders pipeline product include 5-Hydroxytryptamine Receptor 1A Agonist with seven drugs in Phase II. The Appetite (Eating) Disorders pipeline products include seven routes of administration with the top ROA being Oral and four key molecule types in the Appetite (Eating) Disorders pipeline products market including Small Molecule, and Synthetic Peptide.
Appetite (Eating) Disorders overview
Appetite (eating) disorders are psychological conditions that affect how people think and behave regarding food and their body weight and shape. They can cause serious health problems and even death if not treated. Some of the most common types are anorexia nervosa, bulimia nervosa, binge-eating disorder, and avoidant restrictive food intake disorder. People with these disorders may have symptoms such as extreme restriction or bingeing of food, purging behaviors, fear of weight gain, distorted body image, and physical complications. Eating disorders can be caused by various factors, such as genetics, environment, personality, trauma, and culture. Treatment options may include psychotherapy, medication, nutrition counseling, and hospitalization.
For a complete picture of Appetite (Eating) Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
